MicroCures
Dr. Nivaggioli served as CEO of Avicena, a company focused on neurodegenerative diseases, such as ALS, Huntington and Parkinson, where she brought all programs from Phase I to III, with grants from NIH of over $80M and additional funding from VCs. These programs were all licensed at Phase III stage to Marathon Pharma.
Dr. Nivaggioli also served as CEO of Peninsula Skincare labs, a dermaceutical company and QuRetino, a pre-clinical stage dermatology company, as well as holding senior level positions at Gillette Corp R&D. She is currently a managing partner at CN Partners, a consulting firm for dermatology companies, where she is focused on launching a new topical lidocaine product for cosmetic dermatologists using a novel transdermal delivery technology.
She holds a BA from Oberlin College and earned her Master’s degree, as well as Ph.D.. in Bioorganic Chemistry from the University of Toronto. She conducted her post-doctorate work at MIT.
This person is not in the org chart
This person is not in any offices
MicroCures
MicroCures develops biopharmaceuticals that harness innate cellular mechanisms within the body to precisely control the rate and direction of cell migration, offering the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications.